A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H.
Koyama T, et al. Among authors: teshima m.
ESMO Open. 2024 Jun 3;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Online ahead of print.
ESMO Open. 2024.
PMID: 38833968
Free article.